Genfit SA (GNFT) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
GENFIT SA, a biopharmaceutical company focusing on liver diseases, has reported its half-year liquidity contract figures with Crédit Industriel et Commercial, showing 131,000 shares and €700,885.51 on the liquidity account as of June 30, 2024. During the first half of the year, the company traded 1,515,865 shares on the buy side and 1,532,677 shares on the sell side. GENFIT’s diverse R&D portfolio includes programs targeting Acute-on-Chronic Liver Failure and other serious diseases, with a recent highlight being the FDA’s accelerated approval of their drug for Primary Biliary Cholangitis.
For further insights into GNFT stock, check out TipRanks’ Stock Analysis page.
